$1.15
0.44%
Nasdaq, Aug 22, 10:00 pm CET
ISIN
US67577R1023
Symbol
IRD

Ocuphire Pharma Inc Stock price

$1.15
-0.07 5.74% 1M
+0.07 6.48% 6M
-0.04 3.36% YTD
-0.15 11.54% 1Y
-1.38 54.55% 3Y
-8.47 88.05% 5Y
-253.25 99.55% 10Y
-6.05 84.03% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.01 0.44%
ISIN
US67577R1023
Symbol
IRD
Industry

Key metrics

Basic
Market capitalization
$68.9m
Enterprise Value
$27.1m
Net debt
positive
Cash
$41.8m
Shares outstanding
45.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
5.0 | 4.7
EV/Sales
2.0 | 1.8
EV/FCF
negative
P/B
2.9
Financial Health
Equity Ratio
69.4%
Return on Equity
-225.0%
ROCE
-268.8%
ROIC
733.1%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$13.7m | $14.8m
EBITDA
$-64.3m | $8.8m
EBIT
$-64.3m | $-41.7m
Net Income
$-58.6m | $-30.0m
Free Cash Flow
$-28.9m
Growth (TTM | estimate)
Revenue
-28.2% | 34.7%
EBITDA
-477.4% | 128.0%
EBIT
-477.3% | -33.0%
Net Income
-418.8% | 47.8%
Free Cash Flow
-807.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-470.8% | 59.4%
EBIT
-471.0%
Net
-429.4% | -202.7%
Free Cash Flow
-211.4%
More
EPS
$-1.7
FCF per Share
$-0.6
Short interest
2.1%
Employees
-
Rev per Employee
-
Show more

Is Ocuphire Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Ocuphire Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Ocuphire Pharma Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Ocuphire Pharma Inc forecast:

Buy
88%
Hold
13%

Financial data from Ocuphire Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
14 14
28% 28%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 18 18
38% 38%
135%
- Research and Development Expense 30 30
79% 79%
220%
-64 -64
477% 477%
-471%
- Depreciation and Amortization 0.02 0.02
100% 100%
0%
EBIT (Operating Income) EBIT -64 -64
477% 477%
-471%
Net Profit -59 -59
419% 419%
-429%

In millions USD.

Don't miss a Thing! We will send you all news about Ocuphire Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ocuphire Pharma Inc Stock News

Neutral
GlobeNewsWire
7 days ago
– Phase 1/2 trial expected to initiate in 2H 2025 in patients with BEST1 inherited retinal disease RESEARCH TRIANGLE PARK, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced that...
Neutral
GlobeNewsWire
11 days ago
- Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 - - FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation for OPGx-LCA5 - - Positive topline results reported from VEGA-3 and LYNX-2 Phase 3 trials with Phentolamine Ophthalmic Solution 0.75% - - OPGx-BEST1 on track to en...
Neutral
GlobeNewsWire
20 days ago
RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced that George Magrath, M.D.
More Ocuphire Pharma Inc News

Company Profile

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Head office United States
CEO George Magrath
Founded 2018
Website opusgtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today